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Abstract
Background: Airway absorption and bioavailability of inhaled corticosteroids (ICSs) may be influenced by differences in
pharmacokinetic properties such as lipophilicity and patient characteristics such as lung function. This study aimed to further
investigate and clarify the distribution of budesonide and fluticasone in patients with severe chronic obstructive pulmonary
disease (COPD) by measuring the systemic availability and sputum concentration of budesonide and fluticasone, administered
via combination inhalers with the respective long-acting β2-agonists, formoterol and salmeterol.
Methods: This was a randomized, double-blind, double-dummy, two-way crossover, multicenter study. Following a run-in
period, 28 patients with severe COPD (mean age 65 years, mean forced expiratory volume in 1 second [FEV1] 37.5% predicted
normal) and 27 healthy subjects (mean age 31 years, FEV1 103.3% predicted normal) received two single-dose treatments of
budesonide/formoterol (400/12 μg) and salmeterol/fluticasone (50/500 μg), separated by a 4–14-day washout period. ICS
concentrations were measured over 10 hours post-inhalation in plasma in all subjects, and over 6 hours in spontaneously
expectorated sputum in COPD patients. The primary end point was the area under the curve (AUC) of budesonide and
fluticasone plasma concentrations in COPD patients relative to healthy subjects.
Results: Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 μM·hr versus
6.21 μM·hr) and fluticasone (0.84 μM·hr versus 1.50 μM·hr), and the dose-adjusted AUC (geometric mean) ratios in healthy
subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end
point). In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus
fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 μM versus 0.09 μM).
The amount of expectorated fluticasone (percentage of estimated lung-deposited dose) in sputum over 6 hours was significantly
higher versus budesonide (ratio 5.21; p = 0.006). Both treatments were well tolerated.
Conclusion: The relative systemic availabilities of budesonide and fluticasone between patients with severe COPD and healthy
subjects were similar. In patients with COPD, a larger fraction of fluticasone was expectorated in the sputum as compared with
budesonide.
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Background
Chronic obstructive pulmonary disease (COPD) is a pre-
ventable and treatable disease associated with considera-
ble and increasing morbidity and mortality worldwide
[1,2]. It is characterized by progressive airflow limitation
that is not fully reversible [1]. Inhaled corticosteroids
(ICSs) in combination with a long-acting β2-agonist
(LABA) are recommended for the treatment of patients
with severe COPD and a history of repeated exacerbations
[1,3]. Two such combinations, budesonide/formoterol
and salmeterol/fluticasone, are licensed for use in COPD
and a number of randomized, double-blind clinical stud-
ies have demonstrated improvements in lung function
and reduced numbers of exacerbations with their use [4-
7].
Although these combinations both contain an ICS and a
LABA, differences exist with regard to the pharmacoki-
netic and pharmacodynamic properties of both compo-
nents, such as the oral bioavailability and clearance,
volume of distribution and speed of airway uptake, which
may impact on the clinical efficacy and safety of the treat-
ments. The degree of lipophilicity, for example, varies
widely. Budesonide is several times less lipophilic than
fluticasone and, as a result, dissolves more readily in air-
way mucus and is more rapidly absorbed into the airway
tissue and systemic circulation [8-10]. Fluticasone, being
more lipophilic and thus less water soluble, is more likely
to be retained in the lumen of the airways and therefore,
has a greater chance of being removed from the airways by
mucociliary clearance and cough [11]. These differences
in lipophilicity may be particularly relevant in patients
with severe COPD because marked airflow obstruction
will lead to greater proximal deposition of inhaled drugs
[12] and therefore mucociliary clearance. Indeed, previ-
ous studies in patients with asthma and airflow obstruc-
tion have shown that the systemic exposure of fluticasone
is more affected by lung function than budesonide
[13,14].
This is the first study to investigate and clarify the absorp-
tion of the two ICSs, budesonide and fluticasone deliv-
ered via ICS/LABA combination products, in patients with
severe COPD and healthy subjects. The novel aspect of the
study is the assessment of the proportion of ICS that is
expectorated in sputum in patients with severe COPD.
Methods
Study subjects
Subjects were either healthy, as determined by medical
history, physical examination, vital signs, electrocardio-
gram and clinical laboratory tests, or diagnosed with
severe COPD. The inclusion criteria for patients with
severe COPD were: aged ≥ 40 years, COPD symptoms for
≥ 1 year, a smoking history of ≥ 10 pack-years, pre-bron-
chodilatory forced expiratory volume in 1 second (FEV1)
≤ 55% of predicted normal, FEV1/vital capacity (VC) ≤
70%, a productive cough with expectoration at least twice
before noon on most days, and stable symptoms with no
signs of an infection or COPD exacerbation within 1
month prior to study start. Exclusion criteria included
asthma and/or rhinitis before the age of 40 years and use
of β-blocking agents.
Healthy subjects aged ≥ 18 years with a pre-bronchodila-
tory FEV1 ≥ 80% of predicted normal and an FEV1/VC >
70% were eligible for enrollment. Healthy subjects had to
have never been regular smokers and were excluded if they
were judged to have any significant illness or were using
any prescribed medication, or over-the-counter remedies
(except for oral contraceptives), herbal preparations, vita-
mins and mineral supplements ≤ 2 weeks prior to enroll-
ment.
All subjects gave written informed consent to the study
which was conducted in accordance with the Declaration
of Helsinki and Good Clinical Practice guidelines, and
approved by independent ethics committees.
Study design
This was a double-blind, double-dummy, randomized,
two-way crossover, single-dose, multicenter study (Clini-
calTrials.gov number NCT00379028). Severe COPD
patients were enrolled in Germany (one center), the
United Kingdom (one center) and Sweden (one center);
healthy subjects were enrolled at one center in Sweden.
The first subject was enrolled on 4 September 2006 and
the last subject completed the study on 22 July 2007.
COPD patients and healthy subjects attended the clinic at
the beginning and end of run-in (visits 1–2). Informed
consent was obtained at visit 1 and spirometry (FEV1) was
performed at visit 2, from 2 to 8 days before visit 3 (start
of the study drug administration). Forty-eight hours prior
to visit 2, and throughout the study from then on, COPD
patients using ICS or ICS/LABA combination therapies
(budesonide/formoterol or salmeterol/fluticasone) were
switched to equivalent doses of beclomethasone dipropi-
onate (BDP). Use of other corticosteroids (including nasal
and oral) was not permitted throughout the study.
Patients were also not allowed to use long-acting anti-
cholinergics, e.g. tiotropium 48 hours prior to visit 2 and
throughout the study. Healthy subjects were instructed
that no concomitant medication was permitted, except at
the discretion of the study investigator.
Following run-in, eligible participants were randomized
to the treatment sequence. At each treatment visit (visits 3
and 4), study participants received, in random order, one
inhalation of either budesonide/formoterol (Symbicort®Respiratory Research 2009, 10:104 http://respiratory-research.com/content/10/1/104
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Turbuhaler®, AstraZeneca, Lund, Sweden) 400/12 μg
(metered dose) plus placebo by Diskus™ (GlaxoSmithK-
line, Middlesex, UK) or salmeterol/fluticasone (Seretide™
Diskus, GlaxoSmithKline, Middlesex, UK) 50/500 μg plus
placebo by Turbuhaler (Figure 1). COPD patients were
not permitted to use BDP at either treatment visit. All par-
ticipants were instructed and trained by the study investi-
gator or nurse on the correct inhalation technique, and
study drugs were administered at the same time point on
both treatment visits ± 30 minutes. Each treatment visit
was separated by a washout period of 4–14 days.
Randomization codes were assigned in balanced blocks
from a computer-generated list at AstraZeneca Research
and Development, Södertälje. At each center, participants
were randomized strictly sequentially as they became eli-
gible.
Assessments
The primary objective was to evaluate airway tissue avail-
abilities of budesonide and fluticasone in patients with
severe COPD, using the area under the curve (AUC) of the
plasma concentrations for budesonide and fluticasone in
COPD patients relative to healthy subjects as a surrogate
marker for airway tissue availability.
In patients with severe COPD, secondary objectives
included investigating the amounts of budesonide and
fluticasone spontaneously expectorated in sputum (per-
centage of estimated lung-deposited dose [ELDD]) and
the correlation between weight of sputum expectorated,
lung function and the AUCs for budesonide and flutica-
sone.
Blood samples for measuring the pharmacokinetic varia-
bles (AUC, maximum plasma concentration (Cmax), time
for maximum plasma concentration (Tmax) and mean res-
Crossover study design Figure 1
Crossover study design. BUD/FORM = budesonide/formoterol; SAL/FLU = salmeterol/fluticasone; R = randomization.Respiratory Research 2009, 10:104 http://respiratory-research.com/content/10/1/104
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idence time [MRT]) of inhaled budesonide and flutica-
sone in plasma were obtained from all study participants
via an indwelling plastic catheter in the forearm at pre-
decided time points; before (at any time point between
arrival at the clinic in the morning and inhalation of study
drug) and at 10, 20, 40 and 60 minutes, and 2, 4, 6, 8 and
10 hours post-inhalation of the study drug at visits 3 and
4. The validated budesonide and fluticasone assays were
based on a combined method of liquid chromatography-
mass spectrometry (LC-MS/MS).
Since the pharmacokinetics of budesonide and flutica-
sone differ markedly (i.e., the uptake of fluticasone over
the lung to the circulation is slower than for budesonide
and the volume of distribution higher versus budesonide
[14,15]), healthy subjects were used as a control.
Spontaneously expectorated sputum was collected from
severe COPD patients over seven time intervals for up to
6 hours (0–10, 10–20, 20–40, 40–60, 60–120, 120–240,
and 240–360 min) after study drug inhalation. Samples
from each time interval were pooled, frozen immediately
and stored at -20°C until further processing. After thaw-
ing, the entire expectorate was homogenized using an
energetic ultrasonification treatment in combination with
0.1% dithiothreitol, as previously described [16]. Analysis
of the liquidized sputum was performed using an LC-MS/
MS method to measure concentrations of budesonide and
fluticasone propionate. The method was validated accord-
ing to the principles of the FDA Guidance for Industry
Bioanalytical Method Validation [17]. The assay had a
coefficient of variance at lower limit of quantification of ≤
± 20%, in accordance with the FDA Guidelines [17] and
lower and upper limits of detection of 5 nM and 10,000
nM respectively for budesonide, and 5 nM and 100 nM
respectively for fluticasone.
Statistical analysis
All hypothesis testing was done using two-sided alterna-
tive hypotheses with P-values < 5% considered statistically
significant. Based on data from previous studies, the inter-
individual (between-subject) standard deviation for the
ratio of AUC between budesonide and fluticasone in
healthy subjects has been estimated to be 0.29 (pooled)
on the logarithmic scale [8].
Assuming a similar variation among severe COPD
patients, a total of 24 patients per group was required to
give 90% power to detect a 24% reduction (fluticasone
expected to give a lower ratio than budesonide) in the
ratio of AUC (analyzed in a multiplicative model)
between COPD patients and healthy subjects.
The primary end point (AUC for budesonide and flutica-
sone) was assessed by a multiplicative linear mixed-effect
model, with subject as a random factor and treatment,
period, group (severe COPD patient or healthy subject)
and treatment-group interaction as fixed factors, which
was fitted to the individual dose-adjusted AUCs of flutica-
sone and budesonide plasma concentrations.
The relative systemic bioavailability of each ICS was esti-
mated from this model for patients with severe COPD and
healthy subjects, and expressed as the mean AUC ratio
(dose-adjusted) between fluticasone and budesonide. To
address the primary objective, the systemic exposure of
fluticasone and budesonide was estimated from the
model as the mean ratio for the dose-adjusted AUC
between fluticasone and budesonide in severe COPD
patients, and the mean ratio for dose-adjusted AUC
between fluticasone and budesonide in healthy subjects.
The associated 95% confidence intervals (CIs) were calcu-
lated.
The concentrations of budesonide and fluticasone in the
expectorated sputum samples during 6 hours post-inhala-
tion (percentage of the ELDD) were compared in severe
COPD patients using a similar model, with treatment,
period and patient as fixed factors. The correlation
between drug-adjusted AUC and the amount of expecto-
rated sputum for each ICS was investigated using linear
regression on log AUCs and log sputum weights. The
lung-delivered doses of both steroids were calculated by
assuming an ELDD that was 40% of nominal dose for Tur-
buhaler and 15% of nominal dose for Diskus [8].
Safety outcomes were described using descriptive statis-
tics. Safety analyses were performed on all patients who
inhaled one dose or more of the study drug (full analysis
set).
Results
Patient characteristics
Forty-six COPD patients and 44 healthy subjects were
enrolled for the study. Twenty-eight COPD patients
(mean baseline FEV1 37.5% predicted normal) and 27
healthy subjects (mean baseline FEV1 103.3% predicted
normal) were randomized (Figure 2). During the study,
three subjects (5%) withdrew after randomization (two
COPD patients and one healthy subject).
A greater proportion of severe COPD patients were male
(75%) compared with healthy subjects (41%) (Table 1).
Patients with severe COPD were also older and had a
higher body mass index.
Systemic availability of budesonide and fluticasone
The mean plasma AUC values were lower in COPD
patients versus healthy subjects for budesonide (3.07
μM·hr versus 6.21 μM·hr) and fluticasone (0.84 μM·hrRespiratory Research 2009, 10:104 http://respiratory-research.com/content/10/1/104
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versus 1.50 μM·hr) (Table 2A). The dose-adjusted AUC
(geometric mean) ratios in healthy subjects and patients
with severe COPD for plasma budesonide and fluticasone
were similar (2.02 versus 1.80; primary end point) (Table
2B). The healthy subjects/severe COPD patient ratio of the
fluticasone/budesonide ratios was estimated to be 89%,
which was not significant between the drugs.
Pharmacokinetics of budesonide and fluticasone
The pharmacokinetics of budesonide and fluticasone dif-
fered from one another and between the two study popu-
lations investigated. In the patients with severe COPD,
budesonide showed a fast uptake from the airways (Figure
3) with a Tmax of 15.5 min compared with 50.8 min for
fluticasone, and a Cmax of 1.08 μM compared with 0.09
μM for fluticasone (Table 3). In addition, budesonide had
a lower MRT in the systemic circulation compared with
fluticasone (4.41 hrs versus 12.78 hrs, respectively) in
severe COPD patients. In the COPD patients, the plasma
concentration curve showed a more distinct peak for
budesonide than for fluticasone and a similar substance
difference was seen in healthy subjects (Figure 3). How-
ever, there was a tendency for both ICSs to appear in lower
concentrations in severe COPD patients than in healthy
subjects (Figure 3, Table 2).
Budesonide and fluticasone in expectorated sputum over 
the 6-hour collection period in COPD patients
The average weight of expectorated sputum over the 6-
hour collection time period was similar for both treat-
Patient flow Figure 2
Patient flow.Respiratory Research 2009, 10:104 http://respiratory-research.com/content/10/1/104
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ment periods (Figure 4A). The majority of the expecto-
rated fraction of budesonide was retrieved within the first
2 hours, after which very little was added (Figure 4B). In
contrast, fluticasone was continuously expectorated over a
longer time period (Figure 4B). The mean expectorated
amount of fluticasone (a percentage of ELDD; geometric
mean 5.78; 95% CI: 2.59–12.9) was approximately five
times higher than budesonide (geometric mean 1.11;
95% CI: 0.52–2.37) over the 6-hour post-dose time
period (fluticasone/budesonide: geometric mean 5.21;
95% CI: 1.72–15.8; p = 0.006).
Relationship between AUC for budesonide and 
fluticasone, and the amount of drug expectorated and 
lung function in COPD patients
There was a tendency for a negative relationship to exist
between the amount of expectorated fluticasone and the
fluticasone AUC. This was not observed for budesonide
(Figure 5). There was also a tendency for the AUC ratio of
fluticasone to budesonide to decline at lower FEV1 % pre-
dicted normal, i.e. AUC for fluticasone decreases relative
to budesonide in patients with lower lung function (Fig-
ure 6).
Table 1: Demographics and baseline characteristics
Treatment group
Severe COPD patients
n = 28
Healthy subjects*
n = 27
Male, n (%) 21 (75) 11 (41)
Age, years 65 (48-80) 31 (20-65)
BMI, kg/m2 26.5 (21-32) 23.1 (18-29)
FEV1, l 1.10 (0.5-1.9) 3.8 (2.3-5.9)
FEV1, % PN 37.5 (24-51) 103.3 (84-131)
VC, l 2.8 (1.2-5.2) 4.6 (3.5-6.6)
FVC, l 2.7 (1.1-4.9) -
FEV1, % FVC 42.4 (27-60) -
FEV1, % VC 41.6 (26-63) 83.1 (66-103)
Median time since diagnosis, years (range) 8.8 (1-37) -
Median pack-years (range) 40 (10-64) -
Smoking status -
Previous, n 16 -
Habitual, n 22 -
Inhaled ICS at entry
n 18 -
μg/day 777 (160-1600) -
Data are mean (range) unless otherwise indicated. BMI = body mass index; FEV1 = forced expiratory volume in 1 second; FVC = forced vital 
capacity; ICS = inhaled corticosteroid; PN = predicted normal; VC = vital capacity. * Data not collected in healthy subjects on FVC, FEV1, time since 
diagnosis (not applicable [NA]), smoking (NA) and ICS (NA) at study entry.
Table 2: Systemic availability of budesonide and fluticasone
A)
ICS Subject group n AUC (μM·hr) geometric mean CV
Budesonide Healthy subjects 24 6.21 32.7
Severe COPD patients 24 3.07 106.4
Fluticasone Healthy subjects 26 1.50 42.5
Severe COPD patients 23 0.84 46.0
B)
Parameter Dose-adjusted AUC geometric mean ratio 95% CI
HS/COPD for BUD 2.02 1.48, 2.76
HS/COPD for FLU 1.80 1.32, 2.45
FLU/BUD for HS/COPD 0.89 0.58, 1.37
Summary of A) geometric means of area under the curve (AUC) for budesonide and fluticasone and B) geometric mean ratios for dose-adjusted 
AUC
BUD = budesonide; CI = confidence interval; CV = coefficient of variation; FLU = fluticasone; HS = healthy subjects.Respiratory Research 2009, 10:104 http://respiratory-research.com/content/10/1/104
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Discussion
This study demonstrated that after inhalation with a
LABA, plasma levels of budesonide and fluticasone are
lower in patients with severe COPD than in healthy vol-
unteers; however, there is no difference in the AUC ratios
between the two steroids. Fluticasone is present in the
sputum for longer than budesonide resulting in a higher
proportion of the inhaled dose being expectorated in the
sputum.
The study did not demonstrate a difference in the ratio of
the relative systemic availabilities of inhaled budesonide
and fluticasone between healthy subjects and patients
with severe COPD. This finding is counter to previous
clinical studies that have reported a lower systemic bioa-
vailability of fluticasone, but not budesonide, among
patients with marked airway obstruction due to asthma
compared with healthy subjects [13,14,18]. These previ-
ous observations have been partly attributed to the more
Table 3: Summary of pharmacokinetic parameters in plasma for 
severe COPD patients
Treatment n Mean SD/CV
Tmax (min) Budesonide 24 15.5* 7.2*
Fluticasone 23 50.8* 25.4*
MRT (h) Budesonide 24 4.41* 1.59*
Fluticasone 23 12.78* 4.58*
Cmax (μM) Budesonide 24 1.08† 95.9†
Fluticasone 23 0.09† 37.9†
Cmax = maximum concentration; CV = coefficient of variation; MRT = 
mean residence time; SD = standard deviation; Tmax = time to 
maximum concentration.
* Arithmetic mean/SD; † Geometric mean/CV
Mean plasma concentration of budesonide and fluticasone over 10-hour sampling period in severe COPD patients and healthy  subjects Figure 3
Mean plasma concentration of budesonide and fluticasone over 10-hour sampling period in severe COPD 
patients and healthy subjects. Mean (geometric) plasma concentration of budesonide and fluticasone after a single inhala-
tion of budesonide/formoterol (BUD/FORM) (squares) and salmeterol/fluticasone (SAL/FLU) (circles), respectively, in severe 
COPD patients (solid lines) and healthy subjects (dashed lines).
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central deposition of ICS in obstructed airways and the
higher lipophilicity of fluticasone relative to budesonide
[10,11]. Both drugs are likely to be deposited more proxi-
mally in the obstructive airway but being more lipophilic,
fluticasone is less soluble in the airway mucus than budes-
onide and will therefore be present in the proximal air-
ways for longer and thus, is more likely to be cleared from
the airways than budesonide.
Possible reasons for the conflicting results between our
study and these previous studies could include the fact
that we selected patients with severe COPD (mean 37.5%
FEV1 predicted normal) and daily sputum production,
whereas the aforementioned studies were in subjects with
asthma [13,14,18]. This may be of importance given the
fact that mucociliary clearance is impaired in COPD due
to long-term tobacco smoking [19] and the presence of a
compensatory cough mechanism. It can be speculated
that uptransport of the lung deposited dose via cough is
more rapid than via the slow mucociliary mechanism and
that the more rapid cough uptransport in COPD would
alleviate the differences between budesonide and flutica-
sone in the degree of mucociliary clearance compared to
asthma. The extent to which long-term smoking affects
absorption of inhaled steroids over airway epithelium is
not known. A further difference between our study and
previous studies is that we combined budesonide and flu-
ticasone with a LABA (formoterol and salmeterol, respec-
tively), whereas previous studies have used ICSs alone
[13,14,18,20]. Studies have shown that LABAs can affect
mucociliary beat frequency [21-23], potentiate the inhib-
itory effect of ICSs on mucin secretion [24] and increase
mucus hydration [25], although we think these effects are
not likely to be seen after a single dose of LABA.
Our data confirmed previously reported differences in the
pharmacokinetics of both steroids in the severe COPD
population [14,26]. Budesonide was more rapidly
absorbed in the airway tissue compared with the highly
lipophilic fluticasone as evidenced by a budesonide Tmax
of 15.5 minutes compared with 50.8 minutes for flutica-
sone, which is consistent with its contribution to a more
rapid onset of action, as demonstrated when combined to
formoterol, by Cazzola and colleagues [27].
Cumulative mean amounts of expectorated sputum (A) and budesonide and fluticasone (B) over 6-hour collection Figure 4
Cumulative mean amounts of expectorated sputum (A) and budesonide and fluticasone (B) over 6-hour col-
lection. Mean value plots of the amount of (A) expectorated sputum (arithmetic means) and (B) budesonide and fluticasone in 
the expectorated sputum (percentage of estimated lung deposited dose [ELDD], geometric mean), cumulative over the 6-hour 
collection period. UD/FORM = budesonide/formoterol, SAL/FLU = salmeterol/fluticasone.Respiratory Research 2009, 10:104 http://respiratory-research.com/content/10/1/104
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The differences in lung disposition could also have been
influenced by differences in inhaler device and particle
size [28-31]. As reviewed by Newman and Chan [28], par-
ticle size and mode of inhalation are two important deter-
minants of the proportion of ICS that is deposited in the
respiratory tract. A particle with an aerodynamic diameter
of < 5 μm is more likely to be deposited in the bronchi
and bronchioles compared with a particle > 5 μm, which
is deposited to a higher degree in the mouth and throat
[32]. In vitro studies have reported the amount of fine par-
ticles (aerodynamic diameter < 5 μm) to be more than
double with Turbuhaler compared with Diskus [33]. This
may correspond to a higher and more peripheral lung
deposition of budesonide (via Turbuhaler) compared
with fluticasone (via Diskus) [8,29].
A novel observation was the significant difference in the
amount of the two ICSs in expectorated sputum. The
amount of fluticasone expectorated (percentage of ELDD)
was five times higher than for budesonide, supporting our
hypothesis that its greater lipophilicity leads to greater air-
way clearance through mucociliary clearance and/or
cough. On average, approximately 6% of ELDD (geomet-
ric mean) of inhaled fluticasone was expectorated over the
6 hours after drug administration, whereas most of the
1% of budesonide expectorated was within the first two
hours. Whether this finding could result in decreased host
defenses and therefore provide an explanation for the
increased risk of developing pneumonia, as reported in a
number of recent studies with fluticasone alone or in
combination with salmeterol, is an intriguing hypothesis
and one worthy of further evaluation [6,34-36].
There was a weak inverse relationship between systemic
availability, measured as AUC, for fluticasone and the
amount expectorated in the sputum; a higher sputum
clearance of fluticasone resulted in a lower airway tissue
availability. Such a relationship was not observed for
budesonide. Spirometry was not conducted directly
before each treatment period so as not to affect spontane-
The relationship between drug exposure and expectorated steroid for budesonide (A) and fluticasone (B) Figure 5
The relationship between drug exposure and expectorated steroid for budesonide (A) and fluticasone (B). Area 
under the curve (AUC) versus the amount of expectorated ICS. A) Budesonide: p = 0.33; B) fluticasone: p = 0.013 (Spearman's 
rank correlation test).
Dependency of lung obstruction on AUC Figure 6
Dependency of lung obstruction on AUC. The relation-
ship between area under the curve (AUC) ratio for plasma 
concentration of fluticasone (FLU) versus budesonide (BUD) 
and lung function (forced expiratory volume in 1 second 
[FEV1], % predicted normal); p = 0.026 (Spearman's rank cor-
relation test).Respiratory Research 2009, 10:104 http://respiratory-research.com/content/10/1/104
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ous sputum sampling. However, the data suggest that
there was a tendency for lower fluticasone AUC relative to
budesonide in patients with lower FEV1 (% predicted nor-
mal), indicating that higher airway obstruction results in
lower systemic and lung availability of fluticasone relative
to budesonide.
Certain limitations of this analysis should be acknowl-
edged. These include the relatively small sample size and
lack of ICS monocomponent treatment to investigate how
ICS is handled with and without LABAs, which can
increase mucociliary clearance [21-23,37,38]. However,
now that combined therapy is recommended for patients
with severe COPD, we believe the current study is more
clinically relevant. It is also important to note that sputum
was collected upon spontaneous expectoration and there-
fore probably only represents a fraction of the total
amount of sputum produced during this period. Thus, the
absolute amount of ICS measured in the sputum was
likely to be an underestimate, with the remaining sputum
being swallowed before expectoration. Nevertheless, dif-
ferences in expectorated amounts were controlled for
through the cross-over study design, and data were repro-
ducible.
Conclusion
The present study confirmed that plasma levels of both
fluticasone and budesonide are lower in subjects with
severe COPD but did not demonstrate a difference in the
systemic exposure between budesonide and fluticasone in
severe COPD patients relative to healthy subjects. In
patients with COPD, a larger fraction of fluticasone was
recovered in the expectorated sputum than for budeso-
nide, indicating that fluticasone is more extensively
cleared from the airways, while budesonide is more rap-
idly absorbed into the airway tissue.
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